Cargando…

Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis

BACKGROUND AND AIMS: Self-reported questionnaires are useful for estimating the health-related quality of life (HR-QoL), impact of interventions, and prognosis. To our knowledge, no HR-QoL questionnaire has been developed for cardiac amyloidosis (CA). This study aimed to validate Amylo-AFFECT-QOL qu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kharoubi, Mounira, Bézard, Mélanie, Broussier, Amaury, Galat, Arnault, Gounot, Romain, Poullot, Elsa, Molinier-Frenkel, Valérie, Fanen, Pascale, Funalot, Benoit, Itti, Emmanuel, Lemonnier, François, Sing Chadha, Gagan Deep, Guendouz, Soulef, Mallet, Sophie, Zaroui, Amira, Audard, Vincent, Audureau, Etienne, Le Corvoisier, Philippe, Hittinger, Luc, Planté Bordeneuve, Violaine, Lefaucheur, Jean-Pascal, Amiot, Aurélien, Bequignon, Emilie, Bartier, Sophie, Leroy, Vincent, Teiger, Emmanuel, Oghina, Silvia, Damy, Thibaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043221/
https://www.ncbi.nlm.nih.gov/pubmed/36998975
http://dx.doi.org/10.3389/fcvm.2023.1124660
_version_ 1784913096721039360
author Kharoubi, Mounira
Bézard, Mélanie
Broussier, Amaury
Galat, Arnault
Gounot, Romain
Poullot, Elsa
Molinier-Frenkel, Valérie
Fanen, Pascale
Funalot, Benoit
Itti, Emmanuel
Lemonnier, François
Sing Chadha, Gagan Deep
Guendouz, Soulef
Mallet, Sophie
Zaroui, Amira
Audard, Vincent
Audureau, Etienne
Le Corvoisier, Philippe
Hittinger, Luc
Planté Bordeneuve, Violaine
Lefaucheur, Jean-Pascal
Amiot, Aurélien
Bequignon, Emilie
Bartier, Sophie
Leroy, Vincent
Teiger, Emmanuel
Oghina, Silvia
Damy, Thibaud
author_facet Kharoubi, Mounira
Bézard, Mélanie
Broussier, Amaury
Galat, Arnault
Gounot, Romain
Poullot, Elsa
Molinier-Frenkel, Valérie
Fanen, Pascale
Funalot, Benoit
Itti, Emmanuel
Lemonnier, François
Sing Chadha, Gagan Deep
Guendouz, Soulef
Mallet, Sophie
Zaroui, Amira
Audard, Vincent
Audureau, Etienne
Le Corvoisier, Philippe
Hittinger, Luc
Planté Bordeneuve, Violaine
Lefaucheur, Jean-Pascal
Amiot, Aurélien
Bequignon, Emilie
Bartier, Sophie
Leroy, Vincent
Teiger, Emmanuel
Oghina, Silvia
Damy, Thibaud
author_sort Kharoubi, Mounira
collection PubMed
description BACKGROUND AND AIMS: Self-reported questionnaires are useful for estimating the health-related quality of life (HR-QoL), impact of interventions, and prognosis. To our knowledge, no HR-QoL questionnaire has been developed for cardiac amyloidosis (CA). This study aimed to validate Amylo-AFFECT-QOL questionnaire to assess HR-QoL and its prognostic value in CA. METHODS: A self-reported questionnaire, “Amylo-AFFECT” had been designed and validated for CA symptoms evaluation and screening by physicians. It was adapted here to assess HR-QoL (Amylo-AFFECT-QOL) and its prognostic value in CA. To validate the theoretical model, internal consistency and convergent validity were assessed, particularly correlations between Amylo-AFFECT-QOL and the HR-QoL Minnesota Living Heart Failure (MLHF) questionnaire. RESULTS: Amylo-AFFECT-QOL was completed by 515 patients, 425 of whom (82.5%) had CA. Wild-type and hereditary transthyretin amyloidosis (ATTRwt and ATTRv) and immunoglobulin light-chain amyloidosis (AL) were diagnosed in 47.8, 14.7, and 18.8% of cases, respectively. The best HR-QoL evaluation was obtained with five dimensions: “Heart failure,” “Vascular dysautonomia,” “Neuropathy,” “Ear, gastrointestinal, and urinary dysautonomia,” and “Skin or mucosal involvement.” The global Amylo-AFFECT-QOL and MLHF scores showed significant positive correlations (rs = 0.72, p < 0.05). Patients with a final diagnosis of CA had a global Amylo-AFFECT-QOL score significantly higher than the control group composed by patients with other diagnoses (22.2 ± 13.6 vs. 16.2 ± 13.8, respectively, p-value < 0.01). According to the Amylo-AFFECT-QOL global results, ATTRv patients’ QoL was more affected than AL patients’ QoL or ATTRwt patients’ QoL. Patients with a higher HR-QoL score had a greater risk of death or heart transplant after 1 year of follow-up (log-rank < 0.01). CONCLUSION: Amylo-AFFECT-QOL demonstrates good psychometric properties and is useful for quantifying HR-QoL and estimating CA prognosis. Its use may help to improve overall management of patients with CA.
format Online
Article
Text
id pubmed-10043221
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100432212023-03-29 Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis Kharoubi, Mounira Bézard, Mélanie Broussier, Amaury Galat, Arnault Gounot, Romain Poullot, Elsa Molinier-Frenkel, Valérie Fanen, Pascale Funalot, Benoit Itti, Emmanuel Lemonnier, François Sing Chadha, Gagan Deep Guendouz, Soulef Mallet, Sophie Zaroui, Amira Audard, Vincent Audureau, Etienne Le Corvoisier, Philippe Hittinger, Luc Planté Bordeneuve, Violaine Lefaucheur, Jean-Pascal Amiot, Aurélien Bequignon, Emilie Bartier, Sophie Leroy, Vincent Teiger, Emmanuel Oghina, Silvia Damy, Thibaud Front Cardiovasc Med Cardiovascular Medicine BACKGROUND AND AIMS: Self-reported questionnaires are useful for estimating the health-related quality of life (HR-QoL), impact of interventions, and prognosis. To our knowledge, no HR-QoL questionnaire has been developed for cardiac amyloidosis (CA). This study aimed to validate Amylo-AFFECT-QOL questionnaire to assess HR-QoL and its prognostic value in CA. METHODS: A self-reported questionnaire, “Amylo-AFFECT” had been designed and validated for CA symptoms evaluation and screening by physicians. It was adapted here to assess HR-QoL (Amylo-AFFECT-QOL) and its prognostic value in CA. To validate the theoretical model, internal consistency and convergent validity were assessed, particularly correlations between Amylo-AFFECT-QOL and the HR-QoL Minnesota Living Heart Failure (MLHF) questionnaire. RESULTS: Amylo-AFFECT-QOL was completed by 515 patients, 425 of whom (82.5%) had CA. Wild-type and hereditary transthyretin amyloidosis (ATTRwt and ATTRv) and immunoglobulin light-chain amyloidosis (AL) were diagnosed in 47.8, 14.7, and 18.8% of cases, respectively. The best HR-QoL evaluation was obtained with five dimensions: “Heart failure,” “Vascular dysautonomia,” “Neuropathy,” “Ear, gastrointestinal, and urinary dysautonomia,” and “Skin or mucosal involvement.” The global Amylo-AFFECT-QOL and MLHF scores showed significant positive correlations (rs = 0.72, p < 0.05). Patients with a final diagnosis of CA had a global Amylo-AFFECT-QOL score significantly higher than the control group composed by patients with other diagnoses (22.2 ± 13.6 vs. 16.2 ± 13.8, respectively, p-value < 0.01). According to the Amylo-AFFECT-QOL global results, ATTRv patients’ QoL was more affected than AL patients’ QoL or ATTRwt patients’ QoL. Patients with a higher HR-QoL score had a greater risk of death or heart transplant after 1 year of follow-up (log-rank < 0.01). CONCLUSION: Amylo-AFFECT-QOL demonstrates good psychometric properties and is useful for quantifying HR-QoL and estimating CA prognosis. Its use may help to improve overall management of patients with CA. Frontiers Media S.A. 2023-03-14 /pmc/articles/PMC10043221/ /pubmed/36998975 http://dx.doi.org/10.3389/fcvm.2023.1124660 Text en Copyright © 2023 Kharoubi, Bézard, Broussier, Galat, Gounot, Poullot, Molinier-Frenkel, Fanen, Funalot, Itti, Lemonnier, Sing Chadha, Guendouz, Mallet, Zaroui, Audard, Audureau, Le Corvoisier, Hittinger, Planté Bordeneuve, Lefaucheur, Amiot, Bequignon, Bartier, Leroy, Teiger, Oghina and Damy. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Kharoubi, Mounira
Bézard, Mélanie
Broussier, Amaury
Galat, Arnault
Gounot, Romain
Poullot, Elsa
Molinier-Frenkel, Valérie
Fanen, Pascale
Funalot, Benoit
Itti, Emmanuel
Lemonnier, François
Sing Chadha, Gagan Deep
Guendouz, Soulef
Mallet, Sophie
Zaroui, Amira
Audard, Vincent
Audureau, Etienne
Le Corvoisier, Philippe
Hittinger, Luc
Planté Bordeneuve, Violaine
Lefaucheur, Jean-Pascal
Amiot, Aurélien
Bequignon, Emilie
Bartier, Sophie
Leroy, Vincent
Teiger, Emmanuel
Oghina, Silvia
Damy, Thibaud
Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis
title Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis
title_full Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis
title_fullStr Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis
title_full_unstemmed Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis
title_short Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis
title_sort amylo-affect-qol, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043221/
https://www.ncbi.nlm.nih.gov/pubmed/36998975
http://dx.doi.org/10.3389/fcvm.2023.1124660
work_keys_str_mv AT kharoubimounira amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT bezardmelanie amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT broussieramaury amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT galatarnault amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT gounotromain amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT poullotelsa amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT molinierfrenkelvalerie amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT fanenpascale amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT funalotbenoit amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT ittiemmanuel amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT lemonnierfrancois amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT singchadhagagandeep amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT guendouzsoulef amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT malletsophie amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT zarouiamira amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT audardvincent amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT audureauetienne amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT lecorvoisierphilippe amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT hittingerluc amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT plantebordeneuveviolaine amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT lefaucheurjeanpascal amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT amiotaurelien amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT bequignonemilie amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT bartiersophie amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT leroyvincent amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT teigeremmanuel amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT oghinasilvia amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis
AT damythibaud amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis